Cancer vaccines

Global Oncology Launches Vaccine Education Campaign to Eradicate Cervical Cancer, Appointing Nigerian Stock Exchange President as Global Ambassador

Retrieved on: 
Monday, December 21, 2020
Infectious diseases, Pharmaceutical, Health, Oncology, Cancer, Clinical medicine, Medicine, Infectious causes of cancer, Papillomavirus, Gynaecological cancer, Vaccines, Cancer vaccines, HPV vaccine, Cervical cancer, Global Oncology, Vaccine

Global Oncology, a U.S.-based non-profit organization announces the launch of the Cervical Cancer-Free Nigeria (CCFN) campaign, which seeks to eradicate virus-driven diseases such as cervical cancer by educating Nigerians about vaccine safety and efficacy.

Key Points: 
  • Global Oncology, a U.S.-based non-profit organization announces the launch of the Cervical Cancer-Free Nigeria (CCFN) campaign, which seeks to eradicate virus-driven diseases such as cervical cancer by educating Nigerians about vaccine safety and efficacy.
  • View the full release here: https://www.businesswire.com/news/home/20201221005135/en/
    Mr. Abimbola Ogunbanjo, President of the Nigerian Stock Exchange (Photo: Business Wire)
    Im proud to partner with Global Oncology in advancing the CCFN campaign, said Otunba Ogunbanjo.
  • The success of the HPV vaccine campaign and recently initiated COVID-19 vaccine efforts depend on the general public being made aware of vaccine safety, efficacy and availability.
  • This is the mission of the CCFN campaign: to ensure that no Nigerian woman dies of cervical cancer.

Europe $9.87 Bn Preventive Vaccines Market 2020-2026 by COVID-19 Impact, Vaccine Type, Disease, Administration, Patient - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medicine, Vaccines, Medical specialties, Vaccination, Virology, COVID-19 vaccine, Medical research, Vaccine, Cancer vaccines, Autogenous vaccines, Vaccine hesitancy

The "Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Europe preventive vaccines market accounted for $9,879.2 million in 2019 and will grow by 10.28% annually over 2020-2026 owing to the rising healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
  • Specifically, potential risks associated with investing in Europe preventive vaccines market are assayed quantitatively and qualitatively through a Risk Assessment System.

Asia Pacific Preventive Vaccines Market 2020-2026 by COVID-19 Impact, Vaccine Type, Disease, Administration, Patient, and Growth Opportunity - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Virology, Vaccination, Vaccines, Clinical medicine, Vaccine, COVID-19 vaccine, Cancer vaccines, Autogenous vaccines

The "Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Asia Pacific preventive vaccines market will grow by 12.89% annually with a total addressable market cap of $97.2 billion over 2020-2026 owing to the rising healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
  • Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through a Risk Assessment System.

North America Preventive Vaccines Market 2020-2026 by COVID-19 Impact, Vaccine Type, Disease, Administration, & Patient - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Virology, Vaccination, Vaccines, Health sciences, COVID-19 vaccine, Medical research, Vaccine, Cancer vaccines, Autogenous vaccines, Vaccine hesitancy

The "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • North America preventive vaccines market is expected to grow by 9.98% annually in the forecast period and reach $30.01 billion by 2026 driven by increasing healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
  • Specifically, potential risks associated with investing in North America preventive vaccines market are assayed quantitatively and qualitatively through a Risk Assessment System.

SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast

Retrieved on: 
Friday, December 11, 2020
Branches of biology, Cytokines, Granulocyte-macrophage colony-stimulating factor, Clinical medicine, Medicine, Cancer vaccines, Virotherapy, Experimental cancer treatments

This investigator-sponsored trial randomized patients to receive, prior to surgery, either GM-CSF followed by NPS two weeks later or GM-CSF alone.

Key Points: 
  • This investigator-sponsored trial randomized patients to receive, prior to surgery, either GM-CSF followed by NPS two weeks later or GM-CSF alone.
  • The updated data, based on a 6-month follow-up, demonstrate that CD8+ T-cell responses persist long-term post-NPS treatment, with treated patients retaining and modestly enhancing their antigen-specific immune response.
  • Further data from additional analyses of select histologic and molecular biomarkers will be presented in a future scientific meeting.
  • The VADIS data will be presented today, December 11, at the Virtual 2020 Annual San Antonio Breast Cancer Symposium (SABCS)
    Title: Vadis trial: phase II trial of Nelipepimut-S peptide vaccine in women with DCIS of the breast.

Europe Cancer Vaccines Markets, 2019-2020 & 2027 - Dendritic Cells Cancer Vaccines Segment to Grow at Fastest Rate

Retrieved on: 
Thursday, December 10, 2020
Vaccination, Medical specialties, Medicine, Clinical medicine, Vaccines, Vaccine, Virology, Cancer vaccines, Cancer vaccine, Viral vector, Vaccine therapy, Therapeutic vaccines

Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines.

Key Points: 
  • Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines.
  • The in recombinant cancer vaccines segment held the largest share of the market in 2019.
  • Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.
  • Market growth in Europe Cancer Vaccines is mainly due to factors such as increasing prevalence of cancer and rising government initiatives to prevent cancer.

Gardasil Attorneys Allege HPV Vaccine Caused Girl to Develop POTS

Retrieved on: 
Wednesday, November 18, 2020
Vaccination, Papillomavirus, Clinical medicine, Vaccines, Medical specialties, Cancer vaccines, Infectious causes of cancer, Gardasil, HPV vaccine, Vaccine, Human papillomavirus infection

The plaintiff in the case, Sahara Walker of Lake Mills, Wisconsin, received the Gardasil vaccine when she was just 11 years old.

Key Points: 
  • The plaintiff in the case, Sahara Walker of Lake Mills, Wisconsin, received the Gardasil vaccine when she was just 11 years old.
  • Ms. Walker is seeking punitive damages against Merck for creating a substantial risk of significant harm to children and patients who were injected with the Gardasil HPV vaccine .
  • Attorneys representing Sahara Walker further allege that Gardasil contains a secret DNA adjuvant and potentially hazardous ingredient designed to make the vaccine more potent.
  • But since she became sick and disabled within days of getting the shot, we firmly believe her adverse reactions were caused by the Gardasil vaccine.

Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence

Retrieved on: 
Monday, November 16, 2020
Medicine, Clinical medicine, Medical specialties, Vaccination, Vaccines, Cancer vaccines, Cancer vaccine, Vaccine, Melanoma, Oncophage, Herpes simplex research

These results are important because most cancer vaccine trials have failed to show clinical efficacy.

Key Points: 
  • These results are important because most cancer vaccine trials have failed to show clinical efficacy.
  • Sixty patients who had stage 2 or 3 melanoma, and whose cancer was successfully removed via surgery, received the vaccine.
  • Half of the patients received the vaccine alone while the other half received the vaccine with Flt3L and poly-ICLC.
  • Researchers also plan to follow trial participants over time and measure how many have cancer recurrence to further study the vaccine's efficacy in each group.

Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

Retrieved on: 
Wednesday, November 11, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Medicine, Medical specialties, Vaccination, Vaccines, Life sciences, Medical research, Moderna, Cancer vaccines, Cancer vaccine, Vaccine, Moderna’s Immuno-Oncology Programs, Moderna

Moderna also announced that Dr. Praveen Aanur has joined Moderna as Vice President, Therapeutic Area Head for Oncology Development.

Key Points: 
  • Moderna also announced that Dr. Praveen Aanur has joined Moderna as Vice President, Therapeutic Area Head for Oncology Development.
  • We are encouraged by these interim data from our personalized cancer vaccine program, which involves designing and manufacturing a unique vaccine for each patient based on their specific tumor, said Stephen Hoge, M.D., President of Moderna.
  • This study demonstrates the ability of Modernas mRNA personalized cancer vaccine to elicit clinical activity when given in combination with pembrolizumab.
  • Moderna develops and manufactures these investigational PCVs at its personalized vaccines unit within its Massachusetts manufacturing facility.

Outlook on the Cancer Vaccines Worldwide Industry to 2027 - Emerging Markets in Developing Countries Present Opportunities

Retrieved on: 
Thursday, November 5, 2020
Vaccination, Medical specialties, Clinical medicine, Medicine, Vaccine, Virology, Cancer vaccine, Vaccines, Cancer vaccines

6.2 Global Cancer Vaccines Market, By Geography - Forecast And Analysis

Key Points: 
  • 6.2 Global Cancer Vaccines Market, By Geography - Forecast And Analysis
    7.7.2 Whole Cell Cancer Vaccines: Cancer Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
    7.8.2 Viral Vector Cancer Vaccines: Cancer Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
    8.2 Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)
    9.2 Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)
    10.2 Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)
    11.4 Middle East & Africa: Cancer Vaccines Market
    11.5 South and Central America: Cancer Vaccines Market
    13.2 Growth Strategies Done by the Companies in the Market, (%)